Loading clinical trials...

High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma

NCT03007823•Fuda Cancer Hospital, Guangzhou

Summary

The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of melanoma.

Detailed Description

By enrolling patients with small metastases of melanoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of high-activity natural killer cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Eligibility

Age

30 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence
•Body tumor 1-6, the maximum tumor length \< 2 cm
•KPS ≥ 70, lifespan \> 6 months
•Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L

Exclusion Criteria

•Patients with cardiac pacemaker
•Patients with brain metastasis
•Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

Locations (1)

Fuda cancer institute of Fuda cancer hospital

Guangzhou, Guangdong, China

Key Dates

Start Date

December 1, 2016

Primary Completion Date

December 1, 2017

Completion Date

June 1, 2019

Last Updated

September 12, 2019

Enrollment

ACTUAL participants

Conditions

Melanoma

Interventions

High-activity natural killer

BIOLOGICAL

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

RECRUITINGPHASE1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 12, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma

Inclusion Criteria

Exclusion Criteria

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers